Friends! In this video, I'm going to talk about the best 2 stocks to consider
2 extracted signals · 0 resolved · 2 still active
The Patient Investor07 Nov 2025, 00:26 UTC
AI-generated source summary
The analyst reviews two stocks for November. META trades at 21 times forward earnings and with access to 3.5 billion daily active people. Revenue growth is reaccelerating from 16% to 26%. Meta has the potential for higher earnings per share. A significant capital expenditure is leading to Meta's Metaverse moment. The presenter stated that if the capital expenditure takes too long to produce results, the core business is still solid. The presenter estimates a failure bound of $500 and a target of $980. The analyst then covers Cheniere Energy (LNG), an uncorrelated natural gas stock. LNG is down 12% over the last month. The analyst states that Cheniere Energy has the second largest liquefaction facility in the US, providing natural gas to Europe and Asia. LNG's most recent earnings are impressive. The LNG global capacity should increase by 60% by the end of the decade. However, demand is not going to match capacity. The current price is around $205 and their analysis indicates the stock has around $25 DE around 2030 with a price target of $400.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
2 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
2 signals remain active.
Signals in this source
More Prediction Case Files from The Patient Investor
Why I Don't Own Google Stock & When I'm Buying
The CHEAPEST Quality Stock In The Stock Market!
Intuitive Surgical Stock Analysis! Risks & Upside Potential
There Is NO AI BUBBLE! I’m Buying Every Dip
2 Stocks I'm Buying In The Next 2 Weeks
Netflix Stock Is FINALLY A Buy!
The Patient Investor
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

